In SINUS trials, 63% of patients had prior surgery1,2

83%

REDUCTION IN THE
NEED
FOR SINUS
SURGERY

vs placebo through Week 52 (HR: 0.17 [95% CI: 0.07, 0.46])1

74%

REDUCTION IN THE
NEED FOR SYSTEMIC
STEROID USE

vs placebo through Week 52 (HR: 0.26 [95% CI: 0.18, 0.38])1

There was a 76% reduction in the need for surgery and/or systemic steroids vs placebo through Week 52
(HR: 0.24 [95% Cl: 0.17, 0.35]).1,a,b

aIndividually, systemic steroid use reduction and need for sinus surgery were not multiplicity-adjusted endpoints.1,2

bIn SINUS-24 and SINUS-52, DUPIXENT 300 mg Q2W + INCS (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo + INCS (Day 0: n=286; Week 24: n=187; Week 52: n=61).1

HR, hazard ratio; INCS, intranasal corticosteroid; Q2W, once every 2 weeks.